New hope for bladder cancer patients who failed standard treatment
Disease control
Recruiting now
This study tests a new drug called Ruvidar, given directly into the bladder, for people with a type of bladder cancer that did not respond to or could not tolerate standard BCG therapy. About 90 adults will receive up to three treatment sessions. The main goal is to see if the dr…
Phase: PHASE2 • Sponsor: Theralase® Technologies Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC